New approaches to blockade of the renin-angiotensin-aldosterone system: Overview of regulation of the renin-angiotensin-aldosterone system

Journal of Pharmacological Sciences

Volumn 113, Issue 4, 2010, Pages 289-291

  Nishiyama, Akira ^a   Kim Mitsuyama, Shokei ^b  

^a KAGAWA UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Aldosterone; Angiotensin II (AngII); Mineralocorticoid receptor (MR)

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN II [3-8]; ANGIOTENSIN III; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM INHIBITOR; RENIN INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMAN; HYPERTENSION; INFLAMMATION; MITOGENESIS; NONHUMAN; PHARMACOLOGICAL BLOCKING; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; TISSUE INJURY;

EID: 77956218933     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.10R03FM     Document Type: Review

References (21)

1. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59:251-287.
2. Nishiyama A, Hitomi H, Rahman A, Kiyomoto H. Drug discovery for overcoming chronic kidney disease (CKD): pharmacological effects of mineralocorticoid-receptor blockers. J Pharmacol Sci. 2009;109:1-6.
3. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115:114-126.
4. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
5. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, et al. Hypertens Res. 2009;32:3-107.
6. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
7. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
8. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
9. Kobori H, Ozawa Y, Suzaki Y, Prieto-Carrasquero MC, Nishiyama A, Shoji T, et al. Young scholars award lecture: Intratubular angiotensinogen in hypertension and kidney diseases. Am J Hypertens. 2006;19:541-550.
10. Navar LG, Nishiyama A. Why are angiotensin concentrations so high in the kidney? Curr Opin Nephrol Hypertens. 2004;13:107-115.
11. Ichihara A, Kobori H, Nishiyama A, Navar LG. Renal renin-angiotensin system. Contrib Nephrol. 2004;143:117-130.
12. Navar LG, Nishiyama A. Intrarenal formation of angiotensin II. Contrib Nephrol. 2001;135:1-15.
13. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000;52:11-34.
14. Navar LG, Inscho EW, Majid SA, Imig JD, Harrison-Bernard LM, Mitchell KD. Paracrine regulation of the renal microcirculation. Physiol Rev. 1996;76:425-536.
15. Mulrow PJ. Angiotensin II and aldosterone regulation. Regul Pept. 1999;80:27-32.
16. Naruse M, Tanabe A, Sato A, Takagi S, Tsuchiya K, Imaki T, et al. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension. 2002;40:28-33.
17. Kiyomoto H, Rafiq K, Mostofa M, Nishiyama A. Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury. J Pharmacol Sci. 2008;108:399-405.
18. Ueda S. New approaches to blockade of the renin-angiotensin-aldosterone system: Evidence from Randomized Controlled Trials (RCTs) of angiotensin-converting enzyme inhibitors and angiotensin II-receptor blockers-questions remain unsolved. J Pharmacol Sci. 2010;113:292-295.
19. Ichihara A, Sakoda M, Kurauchi-Mito A, Narita T, Kinouchi K, Bokuda K, et al. New approaches to blockade of the renin-angiotensin-aldosterone system: Characteristics and usefulness of the direct renin inhibitor aliskiren. J Pharmacol Sci. 2010;113:296-300.
20. Takai S, Jin D, Miyazaki M. New approaches to blockade of the renin-angiotensin-aldosterone system: Chymase as an important target to prevent organ damage. J Pharmacol Sci. 2010;113:301-309.
21. Nishiyama A, Hasegawa K, Diah S, Hitomi H. New approaches to blockade of the renin-angiotensin-aldosterone system: Mineralocorticoid-receptor blockers exert antihypertensive and renoprotective effects independently of the renin-angiotensin system. J Pharmacol Sci. 2010;113:310-314.